ANI Pharmaceuticals, Inc. (ANIP) Financial Statements
ANI Pharmaceuticals, Inc. (ANIP) reported trailing twelve-month revenue of $978.4M (up 30.9% year on year) and net income of $108.3M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: $173.0M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ANIPANI Pharmaceuticals, Inc.Follow ANIP — free
—
Price chart with a free account
- Market cap
- 1.7B
- P/E TTM
- 15.7
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.02 | 0.03 | 0.06 | 0.08 | 0.13 | 0.18 | 0.20 | 0.21 | 0.21 | 0.22 | 0.32 | 0.49 | 0.61 | 0.88 | 0.98 | |
| Gross profit | — | — | 0.02 | 0.04 | 0.06 | 0.08 | 0.10 | 0.13 | 0.14 | 0.12 | 0.12 | 0.18 | 0.31 | 0.36 | 0.54 | 0.59 | |
| Research & development | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 | 0.02 | 0.02 | 0.01 | 0.02 | 0.03 | 0.04 | 0.05 | 0.05 | |
| Operating income | — | — | 0.00 | 0.02 | 0.03 | 0.02 | 0.03 | 0.04 | 0.02 | -0.02 | -0.04 | -0.04 | 0.05 | 0.00 | 0.11 | 0.15 | |
| Pre-tax income | — | -0.00 | 0.00 | 0.02 | 0.02 | 0.01 | 0.02 | 0.02 | 0.00 | -0.03 | -0.06 | -0.06 | 0.02 | -0.02 | 0.10 | 0.14 | |
| Income tax | — | -0.00 | 0.00 | -0.01 | 0.01 | 0.00 | 0.02 | 0.00 | -0.00 | -0.00 | -0.01 | -0.01 | 0.00 | -0.00 | 0.02 | 0.03 | |
| Net income | -0.05 | -0.01 | 0.00 | 0.03 | 0.02 | 0.00 | -0.00 | 0.02 | 0.01 | -0.02 | -0.04 | -0.05 | 0.02 | -0.02 | 0.08 | 0.11 | |
| Diluted EPS ($) | -3.15 | -1.27 | -0.92 | 2.59 | 1.32 | 0.34 | -0.09 | 1.30 | 0.50 | -1.88 | -3.40 | -3.05 | 0.85 | -1.04 | 3.32 | 4.63 | |
| Diluted shares (bn) | 0.016 | 0.022 | 0.000 | 0.011 | 0.012 | 0.012 | 0.012 | 0.012 | 0.012 | 0.012 | 0.013 | 0.016 | 0.018 | 0.019 | 0.021 | — |
USD billions · SEC XBRL
ANI Pharmaceuticals, Inc. — questions
- What is ANI Pharmaceuticals, Inc.'s revenue?
- $978.4M over the twelve months to 2026-06-30, up 30.9% year on year, from its 10-Q and 10-K filings.
- What is ANI Pharmaceuticals, Inc.'s net income?
- $108.3M over the twelve months to 2026-06-30.
- What is ANI Pharmaceuticals, Inc.'s free cash flow?
- $173.0M over the twelve months to 2026-06-30.
- What are ANI Pharmaceuticals, Inc.'s diluted earnings per share?
- $4.63 over the twelve months to 2026-06-30.
Every figure on this page comes from ANI Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.